Biggest News Aggregation in the World
๐Ÿ“ฐ Lead Compound News

Lead Compound News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Lead Compound. Real-time updates on events, politics, business and more.

BBCNEWS Breakfast April 20, 2017

Parkinsons in their tracks. Iam anti us i am anti Us Air Force Base in south korea where huge Military Exercises are under way. Well hear about the new research that suggests cycling to work cuts the risk of Heart Disease and cancer by almost half. A slowing Global Economy has been blamed for austerity and the financial crisis but data out this week suggests the worlds economy is getting back on its feet. Ill have more on why and what it means for you. And in sport. Serena williams reveals shes ...
20th April Thursday 20th April Brain Diseases Alzheimer S Parkinson S Heart Disease

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

May 06, 2021 published at 7:30 AMglobenewswire PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial GlobeNewswire May 06, 2021 BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall dโ€™Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4 th May the first patient has been dosed w...
Israel General Comunidad Autonoma De Cataluna Manuela Niewel Universitari Vall Laura Soucek Elena Garralda

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial | Comunicados | Edición USA

6 may 2021 PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall dโ€™Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4 th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study,...
Israel General Comunidad Autonoma De Cataluna Manuela Niewel Universitari Vall Laura Soucek Elena Garralda
Source: efe.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science